



SAE Reporting for S1803 - Arm 1 (lenalidomide only)




SAE Reporting for S1803 - Arm 1 (lenalidomide only)




Contact ADR@swog.org with questions.

SAE Reporting for S1803 - Arm 2 (lenalidomide + daratumumab)



SAE Reporting for S1803 - Arm 2 (lenalidomide + daratumumab)



SAE Reporting for S1803 – Tips and Resources

SWOG SAE TEAM (Contact first with all SAE questions, including technical support issues.)

- SAE Email: <mailto:ADR@swog.org>
- SAE Phone: 210-614-8808, Option 3, then Option 7

TIPS

- CTEP-AERS requires each SAE to have an attribution of possible/probable/definite to *something*. If unrelated to protocol treatment and myeloma, an ‘other’ cause may be added in *CTEP-AERS Section 7: Other Causes*. Unknown may be added as an ‘other’ cause if necessary, and an attribution of possible/probable/definite may be assigned to that.
- The seriousness criteria ‘required intervention’ (found in Rave) is only applicable to device trials and should not be selected for S1803.

FREQUENTLY ASKED QUESTIONS

- I’m not sure if this AE requires SAE reporting, should I submit a report just in case?
 - If unsure, the SWOG SAE Team would prefer that you contact us by email or phone to confirm the need to report before spending time submitting an unnecessary report.
- Rave is recommending an SAE report, but the recommendation does not match the SAE reporting requirements in the protocol. Should an SAE report be submitted based on the recommendations in Rave?
 - The Rave recommendations are based on very basic rules and are often incorrect. SAEs should be submitted per protocol guidelines. ADR@swog.org can be contacted anytime for guidance.
- What is the deadline for submitting an SAE report to SWOG?
 - Reporting timeframes are found in the SAE reporting tables within the protocol. SAE tables are found in Section 8 or Section 16 of the protocol.
 - It is important to note that the ‘submission due dates’ in Rave or in the automated CTEP-AERS emails are not true deadlines; these dates only reflect the date after which CTEP-AERS will automatically delete unsubmitted reports.
 - SWOG makes every effort to notify sites if they have a pending report that will soon be deleted, but sites are responsible for reporting within protocol-specified timeframes.

RESOURCES

- Help resources for the CTEP-AERS application:
 - <https://ctepcore.nci.nih.gov/ctepaers/help/webhelp/welcome/help%20-%20welcome%20to%20ctepaers%20help.htm>
- NCI Guidelines for Investigators: Adverse Event Reporting Requirements
 - https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf

SAE Reporting for S1803 – Medidata Rave Flowchart

Adverse Events: Assessment Form

The screenshot shows the 'Adverse Events: Assessment' form in Medidata Rave. The breadcrumb trail at the top includes 'S1803', 'Cycle 18', and 'Adverse Events: Assessment'. The form header contains fields for Patient ID, Enrollment Date, and Patient Initials (LFM). The subject is identified as 288865, and the page title is 'Adverse Events: Assessment - Cycle 18'. An instruction states: 'Please complete this form after each cycle.' The form contains several data entry rows, each with a question, a date, and a 'Yes' button with an eye icon. The 'Reporting period start date' is 31 May 2023, and the 'Reporting period end date' is 28 Jun 2023. The question 'Were adverse events assessed during this time period?' has a 'Yes' response. A follow-up question asks if the patient experienced any adverse events during the reporting period, also with a 'Yes' response. A note indicates the form was opened to the site from the system on 28 Jun 2023. The 'Date of most recent adverse event assessment' is also 28 Jun 2023. A 'Comments' section is visible at the bottom.

Field	Value
Patient ID	[Redacted]
Enrollment Date	[Redacted]
Patient Initials (LFM)	[Redacted]
Subject	288865
Page	Adverse Events: Assessment - Cycle 18
Instructions	Please complete this form after each cycle.
Reporting period start date	31 May 2023
Reporting period end date	28 Jun 2023
Were adverse events assessed during this time period?	Yes
If yes, did the patient experience any adverse events during this reporting period?	Yes
Date of most recent adverse event assessment	28 Jun 2023
Comments	[Redacted]

- Complete the AE Assessment Form in Medidata Rave for the cycle in which the SAE occurred.
 - If mid-cycle, enter current date as the reporting period end date.
 - Once the cycle ends, please amend to the correct reporting period end date.
- Answer Yes to 'Did the patient experience any adverse events during this reporting period?'
 - This will populate the Adverse Events: Report Form.

SAE Reporting for S1803 – Medidata Rave Flowchart

Adverse Events: Report Form

S1803 [redacted] Cycle 18 Adverse Events: Report

Form Instructions ?

* Red asterisk before a field denotes that it is required by the system for rules evaluation.

* Start date of this course/cycle 31 May 2023

* Start date of first course/cycle (derived) 02 Feb 2022

#	* Adverse event term (CTCAE v5.0)	* Adverse event grade description (first 120 characters)	Attribution to study intervention	Treatment received for this AE	If yes, concomitant agent name	None	Hospitalization	Life-threatening	Death	Disability	Congenital anomaly/birth defect	Required intervention	Other	SAE report recommended (derived)
4	Lung infection	(3) IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated	Possible	Yes	Vantin, steroids	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Yes
1	Dyspnea	(2) Shortness of breath with minimal exertion; limiting instrumental ADL	Unrelated	Yes	Nebulizer, albuterol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Yes

- Complete the AE Report form with the following information:
 - CTCAE term
 - Grade
 - Attribution to lenalidomide (Arm 1)
 - Attribution to lenalidomide + daratumumab (Arm 2)
 - Treatment received for AE (Yes/No)
 - Concomitant medications used to treat AE (if known)
- The fields highlighted in green represent seriousness criteria.
 - These fields designate an AE as an SAE.
 - One or more of these fields must be checked for each SAE.
 - Required intervention is only used for device trials.

SAE Reporting for S1803 – Medidata Rave Flowchart

Expedited Reporting Evaluation Form

Patient ID: [REDACTED] Enrollment Date: [REDACTED] Patient Initials (LFM): [REDACTED]

Subject: [REDACTED]
Page: Expedited Reporting Evaluation - Cycle 18

Form Instructions ?

A delay is expected when the safety system is called for AE evaluation.
Note: Do not open more than one ticket per course/cycle in CTEP-AERS. If more than one serious adverse event occurs in this course/cycle, amend the report so both events are entered on the same ticket.

Send all AEs for evaluation

Recommended action for report *(derived)*

An expedited report is RECOMMENDED. If the Investigator believes an expedited report is not warranted, (e.g., per protocol, commercial agent/arm, medical judgement, etc.), edit the 'Recommended action for report' field to indicate 'NONE'. [QC018]
Opened To Site from System (30 Jun 2023)

Click this link to complete the safety report

Report ID *(derived)* REP0743789

Recommended report type *(derived)* CTEP 10 Calendar Day SAE Report

Report due by *(derived)* Monday, July 10, 2023

- Check the box (highlighted in purple) and save the form to send all AEs for evaluation.
 - If no checkbox is available, click the pencil icon to edit this field.
- Click the link (highlighted in green) on the Expedited Reporting Evaluation form to go to CTEP-AERS.
- Detailed instructions for completing the CTEP-AERS report are found:
 - <https://ctepcore.nci.nih.gov/ctepaers/help/webhelp/welcome/help%20-%20welcome%20to%20ctepaers%20help.htm>